Before the race I contacted Aravaipa to inquire about the potential need for a therapeutic use exemption (TUE) for these medications and was told that I didnt need one
Therefore, extensive future research is needed to address these issues and improve the delivery and patient experience [151, 190]
The product is intended for laboratory use, comparative analyses and reference procedures only
In a double-blind study with a placebo group, chronic insomniac patients administered with a DSIP analogue experienced a reduction in sleep latency by an average of 22 minutes, suggesting its potential as a therapeutic agent for severe chronic insomnia patients (Anderer & Saletu, 1991)
Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM